MedReleaf (LEAF) Given New C$30.00 Price Target at Canaccord Genuity

MedReleaf (TSE:LEAF) had its price objective hoisted by Canaccord Genuity from C$21.50 to C$30.00 in a research note released on Wednesday. Canaccord Genuity currently has a buy rating on the stock.

Several other research analysts also recently commented on the stock. Cowen lifted their target price on shares of MedReleaf from C$20.00 to C$36.00 in a report on Monday, January 8th. Eight Capital lifted their target price on shares of MedReleaf from C$13.00 to C$20.00 and gave the stock a buy rating in a report on Wednesday, November 15th.

MedReleaf (TSE LEAF) opened at C$20.40 on Wednesday. The company has a market cap of $2,040.00 and a price-to-earnings ratio of 1,020.00. MedReleaf has a twelve month low of C$6.81 and a twelve month high of C$31.25.

In other news, insider Olam Ltd. Tikun sold 1,000,000 shares of the business’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of C$22.02, for a total transaction of C$22,020,000.00. Also, insider Stephen Arbib sold 50,600 shares of the business’s stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of C$18.00, for a total transaction of C$910,800.00. Insiders sold a total of 1,145,100 shares of company stock worth $25,037,466 in the last quarter.

ILLEGAL ACTIVITY NOTICE: This report was originally published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at

MedReleaf Company Profile

MedReleaf Corp. produces and sells cannabis-based pharmaceutical products in Canada. It offers dried cannabis, cannabis oils, and cannabis oil capsules; and various accessories, including grinders, vaporizers, and lockable containers. The company was incorporated in 2013 and is headquartered in Markham, Canada.

Receive News & Ratings for MedReleaf Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MedReleaf and related companies with's FREE daily email newsletter.

Leave a Reply